Rose Pharma Inc.

Metabolic Disorders

Research activity is centered on obesity and overweight, with attention to appetite regulation and body-weight control.

  • Appetite suppression
  • Food intake regulation
  • Weight management

The sponsor’s clinical work in this area reflects interest in therapeutic approaches for excess body weight and related metabolic health concerns.

Endocrine and Hormonal Pathways

Clinical interest includes GLP-1-related biology, with focus on mechanisms that influence satiety and metabolic signaling.

  • GLP-1 analogue therapy
  • Satiety signaling
  • Metabolic regulation

This area links hormonal pathways to therapeutic strategies for managing eating behavior and energy balance.

Clinical Pharmacology

Research efforts include evaluation of a candidate therapeutic agent for its safety profile and early activity in overweight and obese adults.

  • Safety assessment
  • Preliminary efficacy
  • Therapeutic tolerability

The sponsor’s interest is directed toward pharmacologic intervention in metabolic disease settings.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • Phase 1 randomized, placebo-controlled study of ROSE-010 and paracetamol on appetite in overweight and obese adults

    Not recruiting

    1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Sweden